Article

A study to compare Major Adverse Cardiac Event in patient undergoing PCI with Drug Eluting Stents Vs Bare Metal Stents
Chetan R , Mandev B. Patel

Details

Author

Chetan R

ISSN

2319-5622

DOI

https://doi.org/10.5281/zenodo.1098639

Published on

Aug 11, 2012

Abstract

This study compared Major Adverse Cardiac Event in patient with Acute Coronary Syndromes undergoing PCI with Drug Eluting Stents Vs Bare Metal Stents. A retrospective, observational study was carried out in an inpatient setting of the private tertiary care hospital. Patients with >18 years, diagnosed for Acute Coronary Syndromes (ACS), required intervention in coronary artery with implantation of Drug Eluting Stents (DES) or Bare Metal Stents (BMS) were recruited in the study. The data had been collected from file or database of the hospital. All subjects were followed for major adverse cardiac event. A total of 202 patients who underwent Percutaneous Coronary Intervention (PCI) were enrolled into DES group (N=101) and BMS group (N=101). All patients were followed up at 1 month, 3 months, 6 months & 12 months for Major Adverse Cardiac Events (MACE). Clinical outcomes during 12 months were compared between DES group & BMS group. There was no significant difference in baseline parameters including demographic, risk factors of ACS, diagnosis, angiographic parameters between both groups. Overall MACE rates were reported non-significantly high in BMS group patients (14.85%) compare to DES group patients (8.91%) (P=0.458). However, DES group had lower rates of death (0.99% vs 1.98%, P=0.57), rate of MI (3.96% vs 4.95% P=0.73), rate of revascularization (1.98% vs 3.96% p=0.42) & rate of sub acute thrombosis (1.98% vs 3.96% P=0.42) and higher rate of bleeding (1.98% vs 0.99% p=0.57) compare to cohort-II. The use of DES in the setting of Acute Coronary Syndrome is associated with lower Major Adverse Cardiac Event (MACE) rate compared to BMS without compromising the overall safety over the course of one-year follow-up. The long-term safety of drug-eluting stents needs to be ascertained in large, randomized trials.

Keywords

Drug Eluting Stent (DES), Bare Metal Stent (BMS), Major Adverse Cardiac Event (MACE), Acute Coronary Syndrome (ACS)

Editors-in-Chief


Editors


Upcoming Conferences


Indexing/Listing


Recent Articles

SMALL SCALE LABORATORY CULTURE METHOD PRODUCTION AND CHARACTERIZATION OF L-GLUTAMIC ACID BY E.COLI
Ranjani V. Asha
Published on: Aug 05, 2020
CUBOSOMES : NOVEL EMERGING DRUG DELIVERY SYSTEM
Manasi Nikam* Manasi Nikam*
Published on: Jul 09, 2020
Elements of Pharmaceutical Quality System
Deepthi Suri* Deepthi Suri*
Published on: Jul 07, 2020
A Simple Method Development and Validation for the Determination of Tolbutamide in Bulk and Marketed Dosage Form by UV - Spectrophotometric Technique
Dr. A. Madhukar * Dr. A. Madhukar *
Published on: Jul 06, 2020